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Malignant diseases, as all chronic diseases, follow a distinct
and speciﬁc trajectory that can lead to development of
cachexia. When cachexia develops, patients will often have
a stage of the disease with limited life expectancy. There
are no proven and clinically effective interventions to im-
prove quality of life and/or life expectancy in patients with
cachexia.1 Despite implications for daily practice, the
epidemiology data remain scarce, and several features still
are largely estimates rather than robust information re-
trieved from cross-sectional or prospective observational
studies.2
In this context, contribution by Anker et al. in this issue of
the journal3 is extremely timely and instructive, thus
representing a big important piece in the cancer cachexia jig-
saw. It is the ﬁrst systematic review about cancer cachexia; au-
thors included 21 studies with >31 000 patients, and cancer
cachexia prevalence ranged from 11% to 74%. This information
was then used for estimation of cancer cachexia absolute num-
ber in the USA and European Union (EU), respectively. Overall,
a total of 800 300 patients (15.8 subjects per 10 000 people of
the total EU population) and 527 100 patients (16.5 per 10 000
people of the total US population) are estimated to suffer from
cancer cachexia. Although based on some assumptions (that
usually are needed in diseases deﬁned by arbitrary decisions),
this is the ﬁrst systematic review about cancer cachexia
burden. Findings can be challenged because various cachexia
deﬁnitions were applied, but studies were, nevertheless, con-
ducted by those with speciﬁc interest in the issue and can be
regarded as representative enough. Also, cachexia deﬁnition
changed over time,2,4,5 and no good comparative studies of
various cachexia deﬁnitions are available. An important obser-
vation is the fact that in absolute terms, cachexia of individual
malignancy qualiﬁes as orphan disease, with the prevalence
range from 0.3/10 000 to 3.0/10 000 people of the total pop-
ulation. Although the orphan disease deﬁnition should not be
used as a Trojan horse to bring into the market drugs at higher
prices and to later expand their indication into other therapeu-
tic areas, the identiﬁcation of cancer cachexia as an orphan dis-
ease is novel and can change the landscape of drug
development in this area.
One of key messages from the paper by Anker et al.3 to be
picked up by the research community and clinicians should be
that we need better epidemiological data. As suggested pre-
viously, all available resources should be exploited for use, in-
cluding big data approach, and experience from other disease
should be considered as well.6–9 With existing International
Classiﬁcation of Disease code, only few studies exist.10 None-
theless, because several countries have such nationwide re-
sources,11–13 these could be source of valuable information.
Some ongoing projects linking existing national databases to
get insight into the current clinical practice and physician at-
titudes towards cachexia will provide valuable information.14
Another pathway to be explored is vigilant application of
adopted cachexia deﬁnition in cross-sectional, observational,
and randomized trials involving cancer patients. When com-
bined with outcome data (Figure 1), this would greatly in-
crease our understanding of epidemiological burden and
prognostic implications of this grim condition.
Although the work by Anker et al.3 is focusing on the epide-
miology and prevalence in particular, the implications should
be viewed in a much broader perspective. We deﬁnitely should
argue that reporting cachexia (of chronic disease) is not a part
of daily routine. This can be due to lack of awareness or, even
worse, knowledge about cachexia. Also, it can be due to lack of
any ﬁnancial implications linked with the coding of cachexia.
Can this be overcome? We likely have a strong case for cancer
cachexia, but more effort should be given to increase aware-
ness and to promote diagnostic criteria that can be applied in
daily practice.4,5 However, cancer cachexia is only one aspect
of the syndrome, as cachexia in other clinical conditions as
heart failure and chronic obstructive pulmonary disease can
be deadlier than cancer cachexia.
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In line with cancer but also other disease awareness cam-
paigns,15 a worldwide action to highlight cachexia or more
generally the body wasting could be initiated. The effects
could then be followed with regular analysis of existing data-
bases and scientiﬁc publications describing cachexia. Impor-
tantly, similar strategies should be implied in the case of
sarcopenia, which just recently received the ICD code16 and
has several implications that are similar to those of cachexia.
Simultaneous step would be to promote (epidemiological)
studies in cancer cachexia, with particular emphasis on path-
ophysiology and patient-related outcomes. At the moment,
we do not have any remedy to make patients with cancer ca-
chexia better. Yet there are some encouraging reports17,18
that could inﬂuence future efforts. Combined with the
Figure 1 Prevalence and outcome of cardiac cachexia.
Figure 2 Regulatory pathways for orphan disease drug development in European Union and in the USA.
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current review,3 maybe the most important learning is that
we need to consider cancer cachexia as an orphan disease.
As a result, drug development pathways may be simpliﬁed
with possibility of earlier access programmes.19 Both Euro-
pean Medicines Agency and Food and Drug Administration
have speciﬁc procedures in place that facilitate timely and
more cost-effective translation of basic science into clinical
research and bedside use (Figure 2). The European Medicines
Agency has recently launched the Priority Medicines (PRIME)
scheme 20 to foster research on and development of medi-
cines for patients whose diseases cannot be treated or who
need better treatment options. The PRIME scheme aim is to
support and optimize drug development in order to provide
a faster approval process for those molecules that show rea-
sonable efﬁcacy and safety proﬁles. However, the main prob-
lem with early access programmes is that often adequate
pricing can be difﬁcult to agree because of the greed of com-
panies and unwillingness of the health systems to pay too
much for uncertain effectiveness. In order to overcome these
problems, the PRIME scheme includes the possibility for the
companies to receive scientiﬁc advices together with early
health technology assessments and opinion from patient
groups. This new regulatory pathway has already had and will
have in the future favourable effects on drug development
and with meaningful clinical implications for the therapeutic
areas signiﬁcantly affected by cachexia.
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